Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,834 shares of the biopharmaceutical company’s stock after selling 33,446 shares during the period. Voya Investment Management LLC owned 0.14% of Regeneron Pharmaceuticals worth $109,581,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Pamalican Asset Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $4,915,000. Intact Investment Management Inc. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $356,000. Rhenman & Partners Asset Management AB increased its stake in Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after purchasing an additional 4,457 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% during the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after purchasing an additional 2,828 shares in the last quarter. Finally, Fagan Associates Inc. raised its holdings in Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock worth $9,205,000 after purchasing an additional 3,832 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on REGN. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their target price for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. JPMorgan Chase & Co. decreased their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Finally, Bernstein Bank decreased their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $949.60.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $599.76 on Friday. The firm has a market capitalization of $65.57 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The business’s 50 day simple moving average is $638.93 and its 200-day simple moving average is $728.60. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.